Neoadjuvant therapy as a platform for drug development and approval in breast cancer

Clinical Cancer Research

Volumn 19, Issue 23, 2013, Pages 6360-6370

  Bardia, Aditya ^a   Baselga, José ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BUPARLISIB; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; INHIBITOR OF APOPTOSIS PROTEIN; INIPARIB; LAPATINIB; LCL 161; METFORMIN; METHOTREXATE; NERATINIB; NINTEDANIB; ONARTUZUMAB; PACLITAXEL; PALBOCICLIB; PANITUMUMAB; PERTUZUMAB; RUXOLITINIB; SELUMETINIB; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; DISEASE MARKER; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; EARLY CANCER; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; MINIMAL RESIDUAL DISEASE; NONHUMAN; PATHOLOGIC COMPLETE RESPONSE; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT PLANNING; UNITED STATES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84890263741     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0916     Document Type: Article

References (51)

1. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978;1:53-9.
2. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47:3889-94.
3. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62:2507-16.
4. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer:.ndings from the National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-93.
5. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188-94.
6. Rastogi P, Anderson SJ, Bear H, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2008;26:778-85.
7. Di Masi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-16.
8. Esserman LA, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 2011;306:2608-260.
9. Bardia A, Greenup R, Moy B, Smith B, Baselga J. Pathological complete remission after neoadjuvant chemotherapy predicts improved survival in the various breast cancer subtypes: Systematic review and metaanalyses. Presented at AACR Advances in Breast Cancer Research, San Francisco, CA, 2011. Available at: http://www.aacr.org/home/scientists/meetings-workshops/special-conferences/ previous-specialconferences/2011-2012-special-conferences/advances-in- breastcancerresearch/abstracts/poster-session-a.aspx.
10. Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, et al. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) [abstract]. In: Proceedings of the 35th AnnualCTRCAACR San Antonio Breast Cancer Symposium; 2012 Dec. 4-8; San Antonio, TX. Philadelphia (PA): AACR; 2012. Abstract nr S1-11.
11. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, De Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40.
12. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
13. Baselga J, Cortés J, Kim SB, Ro J, Semiglazov V, Campone M, et al. CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19.
14. FDA News Release. FDA approves Perjeta for neoadjuvant breast cancer treatment. Posted: 2013 Sep. 9; accessed 2013 Oct. 1: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm
15. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
16. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145.
17. Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 2009;27:4693.
18. Von Minckwitz G, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, et al. A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol 31, 2013 (suppl; abstr 1004).
19. Romond EH, Perez EA, Bryant J, Suman VJ, GeyerCE Jr A., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
20. Slamon D, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
22. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER-2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER-2-negative cohort. Lancet 2010;375:377-84.
23. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-60.
24. Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment of breast cancer. J Clin Oncol 2009;27:526-34.
25. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, et al. IMPACT Trialists Group. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-70.
26. Baselga J, Semiglazov V, Van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7.
27. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
28. Bates SE, Amiri-Kordestani L, Giaccone G. Drug development: portals of discovery. Clin Cancer Res 2012;18:23-32.
29. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011;29:166-73.
30. Baselga J, Cortés J, Im S-A, Clark E, Kiermaier A, Ross G, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-Positive,.rst-line metastatic breast cancer. In: Proceedings of the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2012 Dec. 4-8; San Antonio, TX. Philadelphia (PA): AACR; 2012. Abstract nr S5-1.
31. Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res 2013;19:6380-8.
32. Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. J Nucl Med 2013;54:1862-8.
33. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4:162ra154.
34. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-4.
35. De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 2013;10:377-89.
36. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 2012;18:1052-9.
37. Balko JM, Giltnane JM, Schwarz LJ, Sanders ME, Kuba MG, Pinto JA, et al. Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatmentrefractory residual disease [abstract]. In: Proceedings of the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2012 Dec. 4-8; San Antonio, TX. Philadelphia (PA): AACR; 2012. Abstract nr S3-6.
38. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012;366:2438-41.
39. Carey LA, Berry DA, Ollila D, Harris L, Krop IE, Weckstein D, et al. Clinical and translational results of CALGB 40601 2013 ASCO Annual Meeting. J Clin Oncol 31, 2013 (suppl; abstr 500).
40. Robidoux A, Tang G, Rastogi P, Geyer CE. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2 operable breast cancer: NSABP protocol B-41 2013 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr LBA506).
41. Reynolds K, Bhatia A, Cheng X, Smith B, Specht M, Moy B, et al. Impact of single and dual neoadjuvant HER2 directed therapy on clinical outcomes among patients with HER2 positive breast cancer.: systematic review and metaanalyses ASCO Annual Meeting. J Clin Oncol 31, 2013 (suppl; abstr 647).
42. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2011;9:199-207.
43. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010;16:691-8.
44. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, et al. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol 2012;30:4584-6.
45. Tabchy A, Ma CX, Bose R, Ellis MJ. Incorporating genomics into breast cancer clinical trials and care. Clin Cancer Res 2013;19:6371-9.
46. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007;25:2650-5.
47. Rimawi M, Mayer I, Forero A, Nanda R, Goetz MP, Rodriguez AA, et al. A multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy, and without chemotherapy in patients with HER2 overexpressing breast cancer. J Clin Oncol 2013;31:1726-31.
48. Demichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, et al. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res 2013 19:2817-23.
49. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366:310-20.
50. Von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012;366:299-309.
51. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer [abstract]. In: Proceedings of the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2012 Dec. 4-8; San Antonio, TX. Philadelphia (PA): AACR; 2012. Abstract nr S6-5.